Quantum BioPharma Ltd. Announces Unbuzzd Wellness Inc. Hires MNP LLP for PCAOB Audits Ahead of Possible IPO and Company Name Change

Quantum BioPharma's Unbuzzd Wellness Inc., formerly Celly Nutrition Corp., has appointed MNP LLP as its auditor for PCAOB audits, signaling preparations for a potential IPO, following the resignation of Stern & Lovrics LLP. Unbuzzd Wellness, known for its hangover reduction beverage, retains a 20.11% ownership stake in the company, and the audit engagement is considered crucial for future capital raising, with CEO John Duffy stating that the PCAOB-level audits will prepare Unbuzzd Wellness for a possible IPO.

Analysis

Quantum BioPharma Ltd. (NASDAQ: QNTM) has announced a significant step for its portfolio company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), with the appointment of MNP LLP to conduct PCAOB audits in preparation for a potential Initial Public Offering (IPO). This move, following the resignation of Stern & Lovrics LLP at Unbuzzd's request, signals a commitment to heightened financial scrutiny and transparency, crucial for accessing public markets. Notably, the company stated there were no reservations or reportable events in connection with the audits by the predecessor auditor. Unbuzzd Wellness, known for its scientifically-proven beverage unbuzzd™ designed to accelerate alcohol metabolism, has also officially changed its name effective May 23, 2025, a rebranding aimed at aligning its identity with its core product. Quantum BioPharma retains a substantial 20.11% ownership stake in Unbuzzd Wellness (as of March 31, 2025) and is entitled to royalty payments starting at 7% of sales until $250 million is paid, then 3% in perpetuity, underscoring a strong vested interest in Unbuzzd's success. Leadership, including CEO John Duffy and Board Co-Chair Gerry David (former CEO of Celsius Holdings), emphasized that these PCAOB audits are pivotal for Unbuzzd's capital raising efforts and IPO ambitions, building on a February 5, 2025 announcement about retaining a New York investment bank for these purposes. While the auditor change and IPO preparation are positive indicators of strategic progression and potential value unlocking, reliance on royalties and the inherent uncertainties of an IPO process present considerations.

Key Decisions for Investors

• Investors in Quantum BioPharma (QNTM) should monitor the progress of Unbuzzd Wellness Inc.'s PCAOB audits and subsequent IPO developments, as a successful listing could significantly enhance the value of QNTM's 20.11% equity stake and future royalty streams.
• Consider the strategic implications of Unbuzzd's rebranding and leadership with beverage industry experience, which may improve market penetration and sales, directly benefiting QNTM through its ownership and royalty agreement.
• Evaluate the potential risks associated with the auditor change, although stated as amicable and without prior issues, and the general execution risks tied to an IPO and the commercial success of Unbuzzd's single main product.